Changes to the Code
H.R. 5158 · Fair Price Device Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 355 New drugs
10 changes the bill asks for here, 9 carried out
- Carried out:
by striking
except for changes required because of differences
and insertingexcept for changes required or appropriate, as determined by the Secretary, because of differences
; and - Carried out:
by inserting
, including changes as a result of differences that are otherwise permitted under this subsection, such as changes as a result of appropriate differences in the device for use with the new drug
before the semicolon;
- Not carried out:
in clause (vii), by striking the
and
at the end;We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking the QTEXT at the end; - Carried out:
in clause (viii) by striking the period at the end and inserting
; and
; - Carried out:
by inserting after clause (viii) the following new clause:
(ix) if the listed drug referred to in clause (i) is intended for use with a device, relevant information as determined by the Secretary to support that the new drug for use with the device can be expected to have the same clinical effect and safety profile as the listed drug …
- Carried out:
in the matter following clause (ix), as inserted by subparagraph (D), by striking
through (viii)
and insertingthrough (ix)
; and - Carried out:
by striking
except for changes required because of differences
and insertingexcept for changes required or appropriate, as determined by the Secretary, because of differences
; and - Carried out:
by inserting
, including changes as a result of differences that are otherwise permitted under this subsection, such as changes as a result of appropriate differences in the device for use with the new drug
before the semicolon;
- Carried out:
by redesignating subparagraphs (J) through (K) as subparagraphs (K) through (L); and
- Carried out:
by inserting after subparagraph (I) the following:
(J) if the listed drug is intended for use with a device, information submitted in the application is insufficient to show that the new drug for use with the device can be expected to have the same clinical effect and safety profile as the listed drug for use with the device …
§ 355(j)(2)(A)An abbreviated application for a new drug shall contain—(iv)–(vii)
Start of § 355 to (j)(2)(A)(iii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (iv) | (iv) | (iv) | ||
| information to show that the new drug is bioequivalent to the listed drug referred to in clause (i), except that if the application is filed pursuant to the approval of a petition filed under subparagraph (C), information to show that the active ingredients of the new drug are of the same pharmacological or therapeutic class as those of the listed drug referred to in clause (i) and the new drug can be expected to have the same therapeutic effect as the listed drug when administered to patients for a condition of use referred to in clause (i); | information to show that the new drug is bioequivalent to the listed drug referred to in clause (i), except that if the application is filed pursuant to the approval of a petition filed under subparagraph (C), information to show that the active ingredients of the new drug are of the same pharmacological or therapeutic class as those of the listed drug referred to in clause (i) and the new drug can be expected to have the same therapeutic effect as the listed drug when administered to patients for a condition of use referred to in clause (i); | |||
| (v) | (v) | (v) | ||
| information to show that the labeling proposed for the new drug is the same as the labeling approved for the listed drug referred to in clause (i) except for changes required because of differences approved under a petition filed under subparagraph (C) or because the new drug and the listed drug are produced or distributed by different manufacturers; | information to show that the labeling proposed for the new drug is the same as the labeling approved for the listed drug referred to in clause (i) except for changes required [inserted: or appropriate, as determined by the Secretary, ]because of differences approved under a petition filed under subparagraph (C) or because the new drug and the listed drug are produced or distributed by different manufacturers[inserted: , including changes as a result of differences that are otherwise permitted under this subsection, such as changes as a result of appropriate differences in the device for use with the new drug]; | |||
| (vi) | (vi) | (vi) | ||
| the items specified in clauses (ii) through (vi) of subsection (b)(1)(A); | the items specified in clauses (ii) through (vi) of subsection (b)(1)(A); | |||
| (vii) | (vii) | (vii) | ||
| a certification, in the opinion of the applicant and to the best of his knowledge, with respect to each patent which claims the listed drug referred to in clause (i) or which claims a use for such listed drug for which the applicant is seeking approval under this subsection and for which information is required to be filed under subsection (b) or (c)— | a certification, in the opinion of the applicant and to the best of his knowledge, with respect to each patent which claims the listed drug referred to in clause (i) or which claims a use for such listed drug for which the applicant is seeking approval under this subsection and for which information is required to be filed under subsection (b) or (c)— |
§ 355(j)(2)(A)–(B)
(j)(2)(A)(vii)(I)–(III) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (A)(vii)(IV) | (IV) | (IV) | ||
| that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted; and | that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted; and | |||
| (A)(viii) | (viii) | (viii) | ||
| if with respect to the listed drug referred to in clause (i) information was filed under subsection (b) or (c) for a method of use patent which does not claim a use for which the applicant is seeking approval under this subsection, a statement that the method of use patent does not claim such a use | if with respect to the listed drug referred to in clause (i) information was filed under subsection (b) or (c) for a method of use patent which does not claim a use for which the applicant is seeking approval under this subsection, a statement that the method of use patent does not claim such a use[inserted: ; and] | |||
| (A)(ix) | (ix) [inserted: ] | |||
| [inserted: if the listed drug referred to in clause (i) is intended for use with a device, relevant information as determined by the Secretary to support that the new drug for use with the device can be expected to have the same clinical effect and safety profile as the listed drug for use with the device when administered to patients under the conditions specified in the labeling of the drug, which information—] | ||||
| (A)(ix)(I) | (I) [inserted: ] | |||
| [inserted: shall be in addition to information under clauses (i) through (viii) that is relevant, as determined by the Secretary, to the evaluation of the new drug for use with the device and the device proposed for use with the new drug; and] | ||||
| (A)(ix)(II) | (II) [inserted: ] | |||
| [inserted: may include—] | ||||
| (A)(ix)(II)(aa) | (aa) [inserted: ] | |||
| [inserted: information (comparative and non-comparative) regarding the device and its performance, including information about the compatibility of the new drug with the device and information regarding the delivery of the new drug when used with the device;] | ||||
| (A)(ix)(II)(bb) | (bb) [inserted: ] | |||
| [inserted: comparative analyses of the new drug for use with the device and the listed drug for use with its device, including information identifying any differences between the user interface of the new drug and listed drug; information identifying any differences between the user interface of the device proposed for use with the new drug and the device used with the listed drug; and information to show that, despite any such differences, the new drug when used with the device can be expected to have the same clinical effect and safety profile as the listed drug when used with the device when administered to patients under the conditions specified in the labeling of the drug; and] | ||||
| (A)(ix)(II)(cc) | (cc) [inserted: ] | |||
| [inserted: comparative and non-comparative human factors studies.] | ||||
| (A) | The Secretary may not require that an abbreviated application contain information in addition to that required by clauses (i) through ( | The Secretary may not require that an abbreviated application contain information in addition to that required by clauses (i) through ([inserted: ix]). | ||
| (B) | (B) Notice of opinion that patent is invalid or will not be infringed.— | (B) Notice of opinion that patent is invalid or will not be infringed.— | ||
| (B)(i) | (i) Agreement to give notice.— | (i) Agreement to give notice.— | ||
| An applicant that makes a certification described in subparagraph (A)(vii)(IV) shall include in the application a statement that the applicant will give notice as required by this subparagraph. | An applicant that makes a certification described in subparagraph (A)(vii)(IV) shall include in the application a statement that the applicant will give notice as required by this subparagraph. | |||
§ 355(j)Abbreviated new drug applications(4)–(5)
(j)(2)(B)(ii)–(4)(E) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (4)(F) | (F) | (F) | ||
| information submitted in the application is insufficient to show that the drug is bioequivalent to the listed drug referred to in the application or, if the application was filed pursuant to a petition approved under paragraph (2)(C), information submitted in the application is insufficient to show that the active ingredients of the new drug are of the same pharmacological or therapeutic class as those of the listed drug referred to in paragraph (2)(A)(i) and that the new drug can be expected to have the same therapeutic effect as the listed drug when administered to patients for a condition of use referred to in such paragraph; | information submitted in the application is insufficient to show that the drug is bioequivalent to the listed drug referred to in the application or, if the application was filed pursuant to a petition approved under paragraph (2)(C), information submitted in the application is insufficient to show that the active ingredients of the new drug are of the same pharmacological or therapeutic class as those of the listed drug referred to in paragraph (2)(A)(i) and that the new drug can be expected to have the same therapeutic effect as the listed drug when administered to patients for a condition of use referred to in such paragraph; | |||
| (4)(G) | (G) | (G) | ||
| information submitted in the application is insufficient to show that the labeling proposed for the drug is the same as the labeling approved for the listed drug referred to in the application except for changes required because of differences approved under a petition filed under paragraph (2)(C) or because the drug and the listed drug are produced or distributed by different manufacturers; | information submitted in the application is insufficient to show that the labeling proposed for the drug is the same as the labeling approved for the listed drug referred to in the application except for changes required [inserted: or appropriate, as determined by the Secretary, ]because of differences approved under a petition filed under paragraph (2)(C) or because the drug and the listed drug are produced or distributed by different manufacturers[inserted: , including changes as a result of differences that are otherwise permitted under this subsection, such as changes as a result of appropriate differences in the device for use with the new drug]; | |||
| (4)(H) | (H) | (H) | ||
| information submitted in the application or any other information available to the Secretary shows that (i) the inactive ingredients of the drug are unsafe for use under the conditions prescribed, recommended, or suggested in the labeling proposed for the drug, or (ii) the composition of the drug is unsafe under such conditions because of the type or quantity of inactive ingredients included or the manner in which the inactive ingredients are included; | information submitted in the application or any other information available to the Secretary shows that (i) the inactive ingredients of the drug are unsafe for use under the conditions prescribed, recommended, or suggested in the labeling proposed for the drug, or (ii) the composition of the drug is unsafe under such conditions because of the type or quantity of inactive ingredients included or the manner in which the inactive ingredients are included; | |||
| (4)(I) | (I) | (I) | ||
| the approval under subsection (c) of the listed drug referred to in the application under this subsection has been withdrawn or suspended for grounds described in the first sentence of subsection (e), the Secretary has published a notice of opportunity for hearing to withdraw approval of the listed drug under subsection (c) for grounds described in the first sentence of subsection (e), the approval under this subsection of the listed drug referred to in the application under this subsection has been withdrawn or suspended under paragraph (6), or the Secretary has determined that the listed drug has been withdrawn from sale for safety or effectiveness reasons; | the approval under subsection (c) of the listed drug referred to in the application under this subsection has been withdrawn or suspended for grounds described in the first sentence of subsection (e), the Secretary has published a notice of opportunity for hearing to withdraw approval of the listed drug under subsection (c) for grounds described in the first sentence of subsection (e), the approval under this subsection of the listed drug referred to in the application under this subsection has been withdrawn or suspended under paragraph (6), or the Secretary has determined that the listed drug has been withdrawn from sale for safety or effectiveness reasons; | |||
| (4)(J) | (J) [inserted: ] | |||
| [inserted: if the listed drug is intended for use with a device, information submitted in the application is insufficient to show that the new drug for use with the device can be expected to have the same clinical effect and safety profile as the listed drug for use with the device when administered to patients under the conditions specified in the labeling of the drug;] | ||||
| (4)(K) | [inserted: (K)] | |||
| the application does not meet any other requirement of paragraph (2)(A); or | the application does not meet any other requirement of paragraph (2)(A); or | |||
| (4)(L) | [inserted: (L)] | |||
| the application contains an untrue statement of material fact. | the application contains an untrue statement of material fact. | |||
| (5) | (5) | (5) | ||
| (5)(A) | (A) | (A) | ||
| Within one hundred and eighty days of the initial receipt of an application under paragraph (2) or within such additional period as may be agreed upon by the Secretary and the applicant, the Secretary shall approve or disapprove the application. | Within one hundred and eighty days of the initial receipt of an application under paragraph (2) or within such additional period as may be agreed upon by the Secretary and the applicant, the Secretary shall approve or disapprove the application. | |||
Rest of § 355 unchanged